Posted by Michael Wonder on 09 Nov 2018
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
9 November 2018 - Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc’s infection-fighting treatment, Neulasta, at a 33% discount.
The list price of $4,175 per unit set by Coherus is the same as Mylan's biosimilar Fulphila that was approved earlier this year.
Coherus intends to launch the biosimilar, Udenyca, on 3 January, it said on a conference call.
